Repligen Co. (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has earned an average rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $190.25.

A number of analysts have issued reports on RGEN shares. Guggenheim began coverage on Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating on the stock. UBS Group lowered their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Finally, Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th.

Repligen Trading Down 1.1 %

Shares of RGEN stock opened at $135.02 on Friday. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a market cap of $7.54 billion, a PE ratio of 540.08, a price-to-earnings-growth ratio of 4.24 and a beta of 0.95. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $149.19 and its two-hundred day moving average is $150.44.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same quarter last year, the firm posted $0.53 EPS. The business’s quarterly revenue was down 3.2% on a year-over-year basis. Equities analysts predict that Repligen will post 1.45 EPS for the current year.

Insider Activity

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. Andra AP fonden bought a new position in Repligen during the second quarter worth about $25,000. YHB Investment Advisors Inc. acquired a new position in Repligen during the first quarter valued at approximately $26,000. International Assets Investment Management LLC acquired a new position in Repligen during the second quarter valued at approximately $33,000. Lazard Asset Management LLC increased its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new stake in Repligen in the second quarter worth $57,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.